Last time the AMRN association seemed to attract a lot of attention....over 1,000 page views. This time its about Biogen, should have it up tomorrow. Here's what I have so far:
Can Resverlogix's Apabetalone Succeed Where Biogen's Aducanumab Failed
Summary
Biogen's market cap took a $16 billion USD hit after discontinuing two late stage trials for Alzheimer's drug Aducanumab.
This huge drop demonstrates the value the market places on even a potential treatment for this devastating disease.
Biotech players interested in potential treatments for Alzheimer's may want to do some research on Resverlogix's lead compound Apabetalone, currently nearing the end of a Phase 3 trial.
